We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid POC Diagnostic Test for Syphilis Could Produce Results in Under 20 Minutes

By LabMedica International staff writers
Posted on 07 Sep 2022

Syphilis infections continue to be a significant health problem and are particularly threatening in high-risk groups and in people who are pregnant, where congenital syphilis can severely affect pregnancy outcome and infant morbidity. More...

According to the Centers for Disease Control and Prevention (CDC), the rate of primary and secondary syphilis (the most infectious stages of the disease) has increased almost every year since the historic low in 2001–2002, increasing 25.4% during 2020–2021, according to preliminary data. The timely identification and treatment of syphilis can decrease the transmission to others and result in better patient outcomes. Serologic tests are currently available in clinical laboratories for the detection of active syphilis, which require shipping samples to perform tests of moderate or high complexity. There is no rapid point-of-care test currently available to accomplish both screening and confirmation of active syphilis. Now, development of such a test should allow for rapid diagnosis of an active infection and timely patient treatment, thus reducing the overall burden of syphilis in the U.S.

Chembio Diagnostics, Inc. (Hauppauge, NY, USA) has been awarded a USD 3.2 million contract from the CDC for the development and clinical validation of a rapid point-of-care (POC) diagnostic test for syphilis. Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II. The assay will be intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies. The test should require only 10 µL of fingerstick blood, serum, or plasma and produce results in under 20 minutes.

Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Additionally, Chembio has previous experience in the field of rapid syphilis diagnostics through its successful development, validation, and commercialization of DPP HIV-Syphilis. The Chembio DPP HIV-Syphilis Assay is a rapid serologic test for the detection of antibodies to HIV and/or the causative agent of syphilis, Treponema pallidum. Additionally, Chembio has worked to develop a DPP Syphilis Screen and Confirm test, using a CDC licensed reagent with improved liposomal preparation on the nontreponemal test line.

“We are excited to continue expanding our core sexually transmitted disease portfolio with the syphilis screen and confirm assay,” said Javan Esfandiari, Chembio’s Chief Science and Technology Officer. “We look forward to developing a highly sensitive and highly specific test that will potentially enable physicians to diagnose and treat active syphilis in a timely manner. Early and reliable diagnosis and timely treatment can prevent transmission of syphilis as well as the development of severe complications. We are honored to have been selected by the CDC for this award.”

Related Links:
Chembio Diagnostics, Inc. 


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.